Research programme: BH4 synthesis modulators - Quartet Medicine

Drug Profile

Research programme: BH4 synthesis modulators - Quartet Medicine

Alternative Names: QMED-1; QMED-2; Sepiapterin reductase inhibitors

Latest Information Update: 28 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Quartet Medicine
  • Class
  • Mechanism of Action GTP cyclohydrolase modulators; Sepiapterin reductase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation; Pain

Most Recent Events

  • 26 Sep 2016 Pharmacodynamics data from preclinical studies presented at the 16th World Congress on Pain-2016 (WCP-2016)
  • 26 Sep 2016 Pharmacodynamics data from preclinical study in Pain presented at the 16th World Congress on Pain (WCP-2016)
  • 06 Jan 2016 Merck enters into agreement with Quartet Medicine to provide funding for development of BH4 synthesis modulators
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top